SuperworthBiovie EPS BIVI
Diluted earnings per share by quarter and over the last twelve months, from 2013.
- Last 12 months, to Jun 30, 2026
- −$3.16
- Latest quarter, Q4 FY26
- −$0.71
- Fiscal year 2026
- −$3.16
Biovie's earnings per share was −$3.16 over the twelve months to Jun 30, 2026.
In its latest quarter, Q4 FY26, it was −$0.71.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2026 | −$3.16 | n/a |
| FY2025 | −$14.94 | n/a |
| FY2024 | −$79.27 | n/a |
| FY2023 | −$156.00 | n/a |
| FY2022 | −$105.00 | n/a |
| FY2021 | −$1651.00 | n/a |
| FY2020 | −$752.00 | n/a |
| FY2019 | −$79.00 | n/a |
| FY2018 | −$500.00 | n/a |
| FY2017 | n/a | n/a |
| FY2014 | $0.00 | n/a |
| FY2013 | n/a | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q4 FY26 | −$0.71 | n/a | −$3.16 | |
| Q3 FY26 | −$0.70 | n/a | −$4.33 | |
| Q2 FY26 | −$0.77 | n/a | −$5.14 | |
| Q1 FY26 | −$0.98 | n/a | −$8.92 | |
| Q4 FY25 | −$1.88 | n/a | −$14.94 | |
| Q3 FY25 | −$1.51 | n/a | −$21.13 | |
| Q2 FY25 | −$4.55 | n/a | −$39.62 | |
| Q1 FY25 | −$7.00 | n/a | −$57.07 | |
| Q4 FY24 | −$8.07 | n/a | −$79.27 | |
| Q3 FY24 | −$20.00 | n/a | −$96.20 | |
| Q2 FY24 | −$22.00 | n/a | −$119.20 | |
| Q1 FY24 | −$29.20 | n/a | −$147.20 |
Against its peers
Companies in Drug Manufacturers - General nearest Biovie's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| BIVIBiovie | −$3.16 | |
| ATNMActinium Pharmaceuticals | $0.36 | |
| SPROSpero Therapeutics | $0.11 | |
| LFVNLifevantage | $0.40 | −46% a year |
| Peer median | $0.36 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Biovie
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.